Elahere (mirvetuximab soravtansine-gynx) — Medica
Fallopian tube cancer
Initial criteria
- Patient is age ≥ 18 years
- Patient has folate receptor alpha positive disease
- Medication will be prescribed by or in consultation with an oncologist
Approval duration
1 year